-
Mashup Score: 1ASCO 2023 – A Role For Immuno-Oncology In Ovarian Cancer At Last? - 11 month(s) ago
AstraZeneca’s Duo-O trial suggests that excluding Brca-positive patients could be the key to Imfinzi’s apparent success in ovarian cancer.
Source: ScripCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1
Improving human health is the raison d’etre of the biopharma sector. But what can the industry do to safeguard and improve the health of Planet Earth? Executives shared their thoughts with Scrip.
Source: ScripCategories: Healthcare Professionals, Latest HeadlinesTweet
-
Mashup Score: 1
Recent executive moves in the industry include C-suite changes at Fresh Tracks Therapeutics and Protara Therapeutics. Meanwhile, new directors were appointed at Grey Wolf Therapeutics and BioSenic.
Source: ScripCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 4
Despite promising mid-stage data for the Ionis-partnered fesomersen and osocimab, licensed from Aronora, the German major has plumped for asundexian as the priority compound for its Factor XIa efforts.
Source: ScripCategories: Expert Picks, Latest HeadlinesTweet
-
Mashup Score: 1
Novartis’s multiple sclerosis treatment Kesimpta has shot out of the gates and bidding fair to contribute generously to the firm’s coffers, while new cholesterol drug Leqvio struggles, Q1 results show.
Source: ScripCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 1
AstraZeneca’s PD-L1/CTLA-4 combination could soon be rivalling Roche’s regimen, and may offer greater safety and tolerability for liver cancer patients.
Source: ScripCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 1
AstraZeneca has presented more promising data from the PROVENT trial of its antibody combination therapy Evusheld which shows high levels of protection from COVID-19 for at least six months.
Source: ScripCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 1CDR-Life Raises $76m To Develop Next-Generation T-Cell Engagers - 2 year(s) ago
The Swiss biotech has raised an impressive series A round which will go towards the development of T-cell engagers based on its unique technology, with an eye to reducing off-tumor activity.
Source: ScripCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 1Pfizer Picks Pharma Outsider Denton As Next CFO - 2 year(s) ago
David Denton will join Pfizer from the hardware store chain Lowe’s, though he does have prior health care experience working at CVS Health.
Source: ScripCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 1Carlyle Bets Big On Late-Stage Biotech With Abingworth Buy - 2 year(s) ago
Tapping into Abingworth’s pioneering clinical co-development model, the private equity behemoth is using that experience to form Launch Therapeutics which will seek to partner with biotech and biopharma on “best‐in‐class, late‐stage clinical assets [and] bring life‐saving therapies to market better, faster and cheaper.”
Source: ScripCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
RT @ScripIanHaydock: #ASCO23 ASCO 2023 – A Role For Immuno-Oncology In Ovarian Cancer At Last? https://t.co/wxZy0R0pdE